scholarly journals Validation of a Reverse Transcription-Polymerase Chain Reaction-Based Five-Gene Signature in Non-small Cell Lung Cancer

2009 ◽  
Vol 4 (5) ◽  
pp. 670
Author(s):  
Luigi Ruco ◽  
Stefania Scarpino ◽  
Guido Natoli
Keyword(s):  
Lung Cancer ◽  
Polymerase Chain Reaction ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Reverse Transcription ◽  
Gene Signature ◽  
Small Cell ◽  
Small Cell Lung ◽  
Chain Reaction ◽  
Polymerase Chain

scholarly journals Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Ilya Tsimafeyeu ◽  
Evgeny Imyanitov ◽  
Larisa Zavalishina ◽  
Grigory Raskin ◽  
Patrisia Povilaitite ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Polymerase Chain Reaction ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Comparison Study ◽  
Small Cell Lung ◽  
Chain Reaction ◽  
Polymerase Chain

Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non–Small Cell Lung Cancer

2017 ◽  
Vol 40 (6) ◽  
pp. 631-638 ◽  
Author(s):  
Graciela Cruz-Rico ◽  
Alejandro Avilés-Salas ◽  
Manuel Segura-González ◽  
Ana María Espinosa-García ◽  
Laura Alejandra Ramírez-Tirado ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Polymerase Chain Reaction ◽  
Small Cell Lung Cancer ◽  
Real Time ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Chain Reaction ◽  
Polymerase Chain

Detection of group C adenovirus DNA in small-cell lung cancer with the nested polymerase chain reaction

1997 ◽  
Vol 123 (7) ◽  
pp. 377-382 ◽  
Author(s):  
Kazuyoshi Kuwano ◽  
Masayuki Kawasaki ◽  
Ritsuko Kunitake ◽  
Naoki Hagimoto ◽  
Yoshitsugu Nomoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Polymerase Chain Reaction ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Chain Reaction ◽  
Nested Polymerase Chain Reaction ◽  
Polymerase Chain

Adenovirus-Mediatedp53Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer

2000 ◽  
Vol 18 (3) ◽  
pp. 609-609 ◽  
Author(s):  
J. Nemunaitis ◽  
S.G. Swisher ◽  
T. Timmons ◽  
D. Connors ◽  
M. Mack ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Polymerase Chain Reaction ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Terminal Deoxynucleotidyl Transferase ◽  
Enzyme Linked Immunosorbent Assay ◽  
Small Cell Lung ◽  
Chain Reaction ◽  
Polymerase Chain

PURPOSE: To determine the safety and tolerability of adenovirus-mediated p53 (Adp53) gene transfer in sequence with cisplatin when given by intratumor injection in patients with non–small-cell lung cancer (NSCLC).PATIENTS AND METHODS: Patients with advanced NSCLC and abnormal p53 function were enrolled onto cohorts receiving escalating dose levels of Adp53 (1 × 106to 1 × 1011plaque-forming units [PFU]). Patients were administered intravenous cisplatin 80 mg/m2on day 1 and study vector on day 4 for a total of up to six courses (28 days per course). Apoptosis was determined by the terminal deoxynucleotidyl- transferase-dUTP nick–end labeling assay. Evidence of vector-specific sequences were determined using reverse-transcriptase polymerase chain reaction. Vector dissemination and biodistribution was monitored using a series of assays (cytopathic effects assay, Ad5 hexon enzyme-linked immunosorbent assay, vector-specific polymerase chain reaction assay, and antibody response assay).RESULTS: Twenty-four patients (median age, 64 years) received a total of 83 intratumor injections with Adp53. The maximum dose administered was 1 × 1011PFU per dose. Transient fever related to Adp53 injection developed in eight of 24 patients. Seventeen patients achieved a best clinical response of stable disease, two patients achieved a partial response, four patients had progressive disease, and one patient was not assessable. A mean apoptotic index between baseline and follow-up measurements increased from 0.010 to 0.044 (P = .011). Intratumor transgene mRNA was identified in 43% of assessable patients.CONCLUSION: Intratumoral injection with Adp53 in combination with cisplatin is well tolerated, and there is evidence of clinical activity.

Genomic Instability in Patients with Non-Small Cell Lung Cancer Assessed by the Arbitrarily Primed Polymerase Chain Reaction

2008 ◽  
Vol 26 (3) ◽  
pp. 262-268 ◽  
Author(s):  
Jasna Markovic ◽  
Jelena Stojsic ◽  
Svetlana Zunic ◽  
Sabera Ruzdijic ◽  
Nikola Tanic
Keyword(s):  
Lung Cancer ◽  
Polymerase Chain Reaction ◽  
Small Cell Lung Cancer ◽  
Genomic Instability ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Chain Reaction ◽  
Polymerase Chain
Sign in / Sign up

Export Citation Format

Share Document